NABUMETONE - Generic Drug Details
✉ Email this page to a colleague
What are the generic sources for nabumetone and what is the scope of patent protection?
Nabumetone
is the generic ingredient in two branded drugs marketed by Annora Pharma, Aurobindo Pharma Usa, Chartwell Molecules, Chartwell Rx, Copley Pharm, Epic Pharma Llc, Impax Labs Inc, Invagen Pharms, Lgm Pharma, Nostrum Labs Inc, Oxford Pharms, Sciegen Pharms Inc, Watson Labs, and Smithkline Beecham, and is included in fourteen NDAs. Additional information is available in the individual branded drug profile pages.There are twenty drug master file entries for nabumetone. Twenty-five suppliers are listed for this compound.
Summary for NABUMETONE
| US Patents: | 0 |
| Tradenames: | 2 |
| Applicants: | 14 |
| NDAs: | 14 |
| Drug Master File Entries: | 20 |
| Finished Product Suppliers / Packagers: | 25 |
| Raw Ingredient (Bulk) Api Vendors: | 109 |
| Clinical Trials: | 8 |
| Patent Applications: | 7,125 |
| Drug Prices: | Drug price trends for NABUMETONE |
| Drug Sales Revenues: | Drug sales revenues for NABUMETONE |
| What excipients (inactive ingredients) are in NABUMETONE? | NABUMETONE excipients list |
| DailyMed Link: | NABUMETONE at DailyMed |
Recent Clinical Trials for NABUMETONE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Federal University of São Paulo | Phase 4 |
| Fundação de Amparo à Pesquisa do Estado de São Paulo | Phase 4 |
| University of Southern Denmark | N/A |
Pharmacology for NABUMETONE
| Drug Class | Nonsteroidal Anti-inflammatory Drug |
| Mechanism of Action | Cyclooxygenase Inhibitors |
Anatomical Therapeutic Chemical (ATC) Classes for NABUMETONE
US Patents and Regulatory Information for NABUMETONE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sciegen Pharms Inc | NABUMETONE | nabumetone | TABLET;ORAL | 078420-002 | Sep 24, 2008 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Impax Labs Inc | NABUMETONE | nabumetone | TABLET;ORAL | 075189-002 | Sep 24, 2001 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Invagen Pharms | NABUMETONE | nabumetone | TABLET;ORAL | 078671-001 | Mar 7, 2008 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Chartwell Rx | NABUMETONE | nabumetone | TABLET;ORAL | 075280-001 | Feb 25, 2002 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Lgm Pharma | NABUMETONE | nabumetone | TABLET;ORAL | 203166-001 | Aug 30, 2019 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Annora Pharma | NABUMETONE | nabumetone | TABLET;ORAL | 090445-001 | Jan 12, 2011 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for NABUMETONE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Smithkline Beecham | RELAFEN | nabumetone | TABLET;ORAL | 019583-002 | Dec 24, 1991 | ⤷ Sign Up | ⤷ Sign Up |
| Smithkline Beecham | RELAFEN | nabumetone | TABLET;ORAL | 019583-001 | Dec 24, 1991 | ⤷ Sign Up | ⤷ Sign Up |
| Smithkline Beecham | RELAFEN | nabumetone | TABLET;ORAL | 019583-002 | Dec 24, 1991 | ⤷ Sign Up | ⤷ Sign Up |
| Smithkline Beecham | RELAFEN | nabumetone | TABLET;ORAL | 019583-001 | Dec 24, 1991 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
